Literature DB >> 25667146

Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer.

Leanne K Jackson1, Jie Deng2, Sheila H Ridner2, Jill Gilbert3, Mary S Dietrich4, Barbara A Murphy3.   

Abstract

OBJECTIVE: We describe development and preliminary testing of Vanderbilt Head and Neck Symptom Survey-Recurrent/Metastatic (VHNSS-RM) to assess residual symptoms, tumor-related symptoms, and side effects from therapy.
METHODS: Items were identified through patient and provider interviews. Card sort selected high-yield and high-impact items. The VHNSS-RM was administered to 50 patients with recurrent/metastatic head and neck cancer (RMHNC).
RESULTS: The VHNSS-RM includes 12 unique symptoms (diet change, tongue movement affecting speech/swallowing, face/neck swelling, neck/jaw cramping, bad breath, drooling, wound drainage/pain/odor, nasal congestion/drainage, eyes watering, face/tongue/ear/scalp numbness, headaches, and confusion) and 7 unique psychosocial issues (burden to family/friends, lost independence, fear, embarrassment, mood swings, stress, and boredom).
CONCLUSIONS: The VHNSS-RM contains 35 physical and 12 psychosocial issues. The VHNSS-RM is feasible and not overly burdensome. Nineteen unique items may improve palliation to patients with RMHNC.
© The Author(s) 2015.

Entities:  

Keywords:  metastatic head and neck cancer; patient-reported outcomes; recurrent head and neck cancer; symptom burden; toxicities; unique symptoms

Mesh:

Year:  2015        PMID: 25667146     DOI: 10.1177/1049909115569591

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  2 in total

1.  [Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].

Authors:  N Zeller; C-J Busch; P Schafhausen; R Knecht; N Möckelmann
Journal:  HNO       Date:  2014-11       Impact factor: 1.284

2.  A Randomized Feasibility Trial to Evaluate Use of the Jaw Dynasplint to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy.

Authors:  Lauren A Zatarain; Derek K Smith; Jie Deng; Jill Gilbert; Mary S Dietrich; Kenneth J Niermann; Sheila H Ridner; Barbara A Murphy
Journal:  Integr Cancer Ther       Date:  2018-06-28       Impact factor: 3.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.